GLP1R and type 2 diabetes mellitus: Four major RCTs have examined the cardiovascular effects of GLP-1 receptor agonists in participants with T2DM and a history or risk of cardiovascular disease: ELIXA (lixisenatide, n=6,068)13, LEADER (liraglutide, n=9,340)14, SUSTAIN-6 (semaglutide, n=3,297)15, and EXSCEL (extended-release exenatide, n=14,752)16.